Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441 | Completed Phase 3 Results FDA Drug

• 2 other identifiers: 31-10-2742011-000469-11
• Study Type: interventional
• Target: 170
• Locations: 10 countries
• Sites: 80

Brief Summary

The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.

Conditions

Tourette's Disorder

Keywords

Tourette's Disorder; Tic Disorders

Outcome Measures

Primary Outcomes (15)

• Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation

  An Adverse Event (AE) is defined as any untoward medical occurrence in a participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. Treatment emergent adverse events (TEAE) are adverse events occurring after the onset of study drug administration.

  From signing of the informed consent up to 30 days after the last dose (Up to Week 52)

• Number of Participants With Clinically Significant Changes in Laboratory Parameter Values

  The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance.

  Baseline to Week 52

• Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

  Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported.

  Baseline to Week 52

• Number of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)

  Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.

  Baseline to Week 52

• Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score

  The AIMS Scale is an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10) are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28. A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Body Mass Index (BMI)

  The BMI kilogram/meter square (i.e. kg/m\^2) was calculated from the Baseline height and the weight at the current visit using one of the following formulae, as appropriate: Weight (kg) divided by \[Height (meters)\]\^2.

  Baseline and Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

• Number of Participants With Clinically Significant Changes in Vital Signs

  Vital signs assessments included orthostatic (supine and standing) blood pressure (BP) measured as millimeter of mercury \[mmHg\]), heart rate, (measured in beats per minute \[bpm\]), body weight (measured in kilograms \[kg\]) and body temperature. Incidence of clinically relevant abnormal values in heart rate, systolic and diastolic blood pressure and weight were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant has been supine for at least 5 minutes and again after the participant has been standing for approximately 2 minutes, but not more than 3 minutes.

  Baseline to Week 52

• Mean Change From Baseline in Simpson Angus Scale (SAS) Score

  The SAS is a rating scale used to measure Extrapyramidal symptoms (EPS). The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40. A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

  The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)

  The SNAP-IV, ADHD Inattention subscale contains 19 items, items 1 to 9 measure inattention, items 11 to 19 measure hyperactivity/impulsivity, and item 10 for inattention domain that scores the intensity of each item during the last seven days on a 0 to 3 scale (0=not at all, 1=just a little, 2=pretty much, 3=very much). The lowest possible score is 0; highest is 57. The negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score

  The CY-BOCS is used to assess characteristics of obsession and compulsion for the week prior to the interview. Nineteen items are rated in the CY-BOCS, but the total score is the sum of only items 1 to 10 (excluding items 1b and 6b). The obsession and compulsion subtotals are the sums of items 1 to 5 (excluding 1b) and 6 to 10 (excluding 6b), respectively. A missing value for any CY-BOCS item scale could result in a missing total score or obsession and compulsion subtotals of which the item scale is a component. At baseline, the full CY-BOCS interview is conducted. At all post-baseline time points, the "Questions on Obsessions" (items 1 to 5) and "Questions on Compulsions" (items 6 to 10) are reviewed and the target symptoms identified at baseline are the primary focus for rating severity. CY-BOCS total score could range from 0 to 40. Higher scores indicate worse outcome. A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score

  The CDRS-R is composed of 17 interviewer-rated symptom areas: impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas. A missing value for any CDRS-R item scale or a not rated item scale (indicated by the value of 0) could result in a missing total score. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome. A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score

  The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. Information is elicited from the child and parent(s) and the rater then combines information from all informants using his/her best judgment. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS rating is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score is the sum of items 2, 3, 5, 6, and 7. The total severity score ranges from 0 to 25, with 25 being the worst. Codes "8" (Not applicable) and "9" (Does not know) are not included in the summation (ie, equivalent to a score of 0 in the summation). A negative change from Baseline indicates improvement.

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Body Weight

  Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Waist Circumference

  Waist circumference was recorded before a participant's meal and at approximately the same time at each visit. Measurement was accomplished by locating the upper hip bone and the top of the right iliac crest and placing the measuring tape in a horizontal plane around the abdomen at the level of the crest. Before reading the tape measure, the assessor assured that the tape was snug, but did not compress the skin, and is parallel to the floor. The measurement was made at the end of a normal exhalation.

  Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)

Secondary Outcomes (6)

• Mean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Mean Change From Baseline in Total YGTSS Score

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Response Rates

  Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)

• Treatment Discontinuation Rates

  Up to Week 53

Study Arms (1)

Aripiprazole

EXPERIMENTAL

Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.

Drug: Aripiprazole

Interventions

Aripiprazole DRUG

Aripiprazole tablets orally once daily.

Also known as: ABILIFY

Aripiprazole

Eligibility Criteria

• Age: 7 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• The participants successfully completed the final assessment visit in either Study 31-10-272 (NCT01418339) or 31-10-273 (NCT01418352). The participants completed all required assessments for the Week 8/Early Termination Visit to be eligible for rollover in to this open-label trial.
• Written informed consent form (ICF) obtained from a legally acceptable representative \& informed assent at Baseline as applicable by trial center's Institutional review board/independent ethics committee (IRB/IEC).
• The participant, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.

You may not qualify if:

• The participants experienced adverse events (AEs) during the double-blind study 31-10-272 (NCT01418339) or 31-10-273 (NCT01418352) that would, in the investigator's judgment, preclude further exposure to aripiprazole.
• The participants had protocol violations during the double-blind trial considered major in the judgment of the investigator which would deem the participant a poor candidate for the trial.
• A positive drug screen at baseline for cocaine, alcohol or other drugs of abuse which will result in early termination at Week 1.
• Sexually active patients who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 90 and 30 days following the last dose of study drug for male and female respectively.
• Participants representing Risk of committing suicide.
• Body weight lower than 16 kg.
• Abnormal laboratory test results (Platelet, Hemoglobin, Neutrophils, Aspartate aminotransferase, Alanine aminotransferase, Creatinine) vital signs and Electrocardiogram (ECG) results.

Sponsors & Collaborators

• Otsuka Pharmaceutical Development & Commercialization, Inc.: lead

Study Sites (80)

Unknown Facility

Dothan, Alabama, 36303, United States

Location

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Los Angeles, California, 90095, United States

Location

Unknown Facility

Sacramento, California, 95815, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

San Francisco, California, 94143, United States

Location

Unknown Facility

Santa Ana, California, 92701, United States

Location

Unknown Facility

Wildomar, California, 92595, United States

Location

Unknown Facility

Gainesville, Florida, 32610, United States

Location

Unknown Facility

Hialeah, Florida, 33012, United States

Location

Unknown Facility

Miami, Florida, 33126, United States

Location

Unknown Facility

Orange City, Florida, 32763, United States

Location

Unknown Facility

St. Petersburg, Florida, 33701, United States

Location

Unknown Facility

Atlanta, Georgia, 30308, United States

Location

Unknown Facility

Atlanta, Georgia, 30329, United States

Location

Unknown Facility

Chicago, Illinois, 60612, United States

Location

Unknown Facility

Indianapolis, Indiana, 46202-5200, United States

Location

Unknown Facility

Overland Park, Kansas, 66211, United States

Location

Unknown Facility

New Orleans, Louisiana, 70114, United States

Location

Unknown Facility

Bloomfield Hills, Michigan, 48302, United States

Location

Unknown Facility

Omaha, Nebraska, 68131, United States

Location

Unknown Facility

Manhasset, New York, 11030, United States

Location

Unknown Facility

Staten Island, New York, 10312, United States

Location

Unknown Facility

Avon Lake, Ohio, 44012, United States

Location

Unknown Facility

Cincinnati, Ohio, 45229-3039, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Unknown Facility

Middleburg Heights, Ohio, 44130, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73112, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19139, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

San Antonio, Texas, 78258, United States

Location

Unknown Facility

Salt Lake City, Utah, 84106, United States

Location

Unknown Facility

Charlottesville, Virginia, 22903, United States

Location

Unknown Facility

Bothell, Washington, 98011, United States

Location

Unknown Facility

La Crosse, Wisconsin, 54601, United States

Location

Unknown Facility

Rousse, 7004, Bulgaria

Location

Unknown Facility

Sofia, 1431, Bulgaria

Location

Unknown Facility

Varna, 9010, Bulgaria

Location

Unknown Facility

Calgary, T3B 6A8, Canada

Location

Unknown Facility

Kelowna, V1Y 1Z9, Canada

Location

Unknown Facility

Toronto, M5B 1T9, Canada

Location

Unknown Facility

Toronto, M5T 2S8, Canada

Location

Unknown Facility

Whitby, L1N 8M7, Canada

Location

Unknown Facility

Aachen, 52074, Germany

Location

Unknown Facility

Dresden, 1307, Germany

Location

Unknown Facility

Hanover, 30625, Germany

Location

Unknown Facility

München, 80336, Germany

Location

Unknown Facility

Ulm, 89075, Germany

Location

Unknown Facility

Budapest, 1021, Hungary

Location

Unknown Facility

Szeged, 6725, Hungary

Location

Unknown Facility

Culiacán, 80020, Mexico

Location

Unknown Facility

Durango, 34000, Mexico

Location

Unknown Facility

León, 37000, Mexico

Location

Unknown Facility

Miguel Hidalgo, 11000, Mexico

Location

Unknown Facility

Monterrey, 64710, Mexico

Location

Unknown Facility

Bucharest, 41915, Romania

Location

Unknown Facility

Cluj-Napoca, 400660, Romania

Location

Unknown Facility

Craiova, 200620, Romania

Location

Unknown Facility

Iași, 700265, Romania

Location

Unknown Facility

Gyeonggi-do, 420-767, South Korea

Location

Unknown Facility

Gyeongsang, 626-770, South Korea

Location

Unknown Facility

Incheon, 400-711, South Korea

Location

Unknown Facility

Seoul, 110-744, South Korea

Location

Unknown Facility

Seoul, 138-736, South Korea

Location

Unknown Facility

Seoul, 143-729, South Korea

Location

Unknown Facility

Changhua, 50006, Taiwan

Location

Unknown Facility

Kaohsiung City, 83301, Taiwan

Location

Unknown Facility

Taichung, 40447, Taiwan

Location

Unknown Facility

Taipei, 100, Taiwan

Location

Unknown Facility

Taipei, 114, Taiwan

Location

Unknown Facility

Donetsk, 83008, Ukraine

Location

Unknown Facility

Kharkiv, 61068, Ukraine

Location

Unknown Facility

Kharkiv, 61153, Ukraine

Location

Unknown Facility

Kyiv, 03049, Ukraine

Location

Unknown Facility

Kyiv, 4209, Ukraine

Location

Unknown Facility

Luhansk, 91045, Ukraine

Location

Unknown Facility

Poltava, 36006, Ukraine

Location

Unknown Facility

Stepanovka, 73488, Ukraine

Location

Unknown Facility

Vinnytsia, 21005, Ukraine

Location

MeSH Terms

Conditions

Tourette Syndrome; Tic Disorders

Interventions

Aripiprazole

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neurodevelopmental Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Results Point of Contact

• Title: Global Clinical Development
• Organization: Otsuka Pharmaceutical Development & Commercialization, Inc.

clinicaltransparency@otsuka-us.com

1-609-524-6788

Study Officials

• Eva Kohegyi, MD

  Otsuka Pharmaceutical Development & Commercialization, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 1, 2011
• First Posted: August 15, 2011
• Study Start: October 19, 2011
• Primary Completion: March 13, 2014
• Study Completion: March 13, 2014
• Last Updated: October 7, 2021
• Results First Posted: October 7, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR
• Time Frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
• Access Criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/.

Locations

CA (5); ME (5); KR (6); DE (5); HU (2); US (36); BU (3); TW (5); UA (9); RO (4)